Antibiotic News and Research RSS Feed - Antibiotic News and Research

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
Multidrug-resistant bacteria can naturally relinquish its ability to resist antibiotics

Multidrug-resistant bacteria can naturally relinquish its ability to resist antibiotics

Infections with one of the most troublesome and least understood antibiotic-resistant "superbugs" are increasing at alarming rates, particularly in health-care settings. [More]
Two antioxidant supplements effective in treating mice with skin-picking disorder

Two antioxidant supplements effective in treating mice with skin-picking disorder

Two antioxidant supplements are effective in treating skin-picking disorder in mice, according to a study led by a Stanford University School of Medicine researcher. [More]
UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

UTHealth scientist receives $1.9 million from NIH to develop non-antibiotic treatment for C. diff infections

Charles Darkoh, Ph.D., a researcher at The University of Texas Health Science Center at Houston School of Public Health, was recently awarded a five-year, $1.9 million R01 grant by the National Institutes of Health to develop a non-antibiotic treatment for Clostridium difficile (C. diff) infections. [More]
Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis expands, accelerates current AR-301 Phase 2a study for treatment of acute pneumonia in the U.S.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin, the company's fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and ventilator-associated pneumonia (HAP and VAP) caused by Staphylococcus aureus, including multi-drug resistant 'MRSA' strains. [More]
Bacterial biofilms play role in development of systemic lupus erythematosus

Bacterial biofilms play role in development of systemic lupus erythematosus

Lupus, multiple sclerosis, and type-1 diabetes are among more than a score of diseases in which the immune system attacks the body it was designed to defend. But just why the immune system begins its misdirected assault has remained a mystery. [More]
Researchers awarded grant from British Council to reduce burden of infectious disease in Malaysia

Researchers awarded grant from British Council to reduce burden of infectious disease in Malaysia

A group of collaborators led by the University of Southampton have been awarded a British Council Newton Fund Institutional Links Grant to support ground-breaking research towards reducing the burden of infectious disease in Malaysia. [More]
Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Is it possible to predict the evolution of the influenza virus? Or how rapidly bacteria evolve resistance to antibiotics? Or even how cancer cells spread inside a human being? These are some of the main topics of discussion that bring together renowned scientists from all over the world at the scientific conference "Forecasting evolution?" held at the Calouste Gulbenkian Foundation (FCG; Portugal) from 8th to 11th July. [More]
Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Dr. Jian-Dong Li receives $1.6 million to develop novel therapeutic targets to treat middle-ear infections

Dr. Jian-Dong Li, a professor and director of the Institute for Biomedical Sciences at Georgia State University and a Georgia Research Alliance Eminent Scholar in Inflammation and Immunity, has received a five-year, $1.6 million federal grant to develop novel anti-inflammatory therapeutics against middle-ear infections. [More]
New collection of papers adds to mounting evidence of gut microbiome’s influential role in health

New collection of papers adds to mounting evidence of gut microbiome’s influential role in health

A newly released collection of papers, the result of the Gut in Focus Symposium Nobel Forum held earlier this year, is adding to the mounting evidence of the influential role the gut microbiome plays in health. [More]
Multiple courses of antibiotics may have significant impact on child development

Multiple courses of antibiotics may have significant impact on child development

A new animal study by NYU Langone Medical Center researchers adds to growing evidence that multiple courses of commonly used antibiotics may have a significant impact on children's development. [More]
National trial aims to reduce unnecessary use of antibiotics in post-acute and long-term care facilities

National trial aims to reduce unnecessary use of antibiotics in post-acute and long-term care facilities

The University of Pittsburgh School of Medicine will be leading a $1.5 million national trial to examine methods to reduce unnecessary use of antibiotics in post-acute and long-term care (PA/LTC) facilities. [More]
Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis' Aerucin gets FDA Fast Track Designation for treatment of hospital-acquired and ventilator-associated pneumonia

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to its fully human monoclonal antibody Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. [More]
Rare genetic variants in A2ML1 gene responsible for chronic middle ear infections, say researchers

Rare genetic variants in A2ML1 gene responsible for chronic middle ear infections, say researchers

Many parents have heard the night-time cry of "my ear hurts." For some children, this might happen frequently beginning in infancy and even persist into adulthood. An international consortium led by those at Baylor College of Medicine may have taken the first step on the road to understanding why only some people get frequent painful or chronic middle ear infections. The culprit may be rare genetic variants in a gene called A2ML1. [More]
IPs spend more time in collecting and reporting hospital infection data than protecting patients

IPs spend more time in collecting and reporting hospital infection data than protecting patients

Collecting and reporting hospital infection data to federal health agencies takes more than 5 hours each day, at the expense of time needed to ensure that frontline healthcare personnel are adhering to basic infection prevention practices such as hand hygiene, according to a recent case study, to be presented on Saturday, June 27 at the 42nd Annual Conference of the Association for Professionals in Infection Control and Epidemiology. [More]

Pilot antibiotic program at pediatric long-term care facility decreases use of topical antibiotic

A pilot antibiotic stewardship program at a pediatric long-term care facility brought about a 59 percent decrease in use of a topical antibiotic and an 83 percent decrease in orders for antibiotics without proper documentation during a six-month period, according to a new study. [More]
World MRSA Day Kickoff Event and Global C. difficile Summit to be held on September 26, 2015 in Illinois

World MRSA Day Kickoff Event and Global C. difficile Summit to be held on September 26, 2015 in Illinois

Methicillin-resistant Staphyloccocus aureus (MRSA), the antibiotic resistant form of Staphylococcus aureus is rampant in U.S. healthcare facilities, in the community, in livestock and in the environment. [More]
Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea announces UK launch of broad-spectrum Cephalosporin Zevtera for first-line treatment of pneumonia

Basilea Pharmaceutica AG today announces the UK launch of its broad-spectrum Cephalosporin Zevtera (Ceftobiprole medocaril) for the first-line treatment of serious bacterial pneumonia. [More]
Study: Cellular respiration separates effects of bactericidal and bacteriostatic antibiotics

Study: Cellular respiration separates effects of bactericidal and bacteriostatic antibiotics

Antibiotics are the mainstay in the treatment of bacterial infections, and together with vaccines, have enabled the near eradication of infectious diseases like tuberculosis, at least in developed countries. [More]
Researchers identify fast and accurate approach to diagnose respiratory tract infection

Researchers identify fast and accurate approach to diagnose respiratory tract infection

Researchers from the University of Manchester are part of a team that has identified an important new approach to diagnose infections in critically ill patients rapidly and accurately. [More]
Dipexium Pharmaceuticals intends to sell common stock in underwritten public offering

Dipexium Pharmaceuticals intends to sell common stock in underwritten public offering

Dipexium Pharmaceuticals, Inc., a late stage pharmaceutical company focused on the development and commercialization of Locilex (pexiganan cream 0.8%), today announced it intends to offer and sell common stock in an underwritten public offering. [More]
Advertisement
Advertisement